Abstract Kallistatin, a plasma protein, exerts pleiotropic effects in inhibiting angiogenesis, inflammation and tumor growth. Canonical Wnt signaling is the primary pathway for oncogenesis in the mammary gland. In this study, we demonstrate that kallistatin bound to the Wnt coreceptor low-density lipoprotein receptor-related protein 6 (LRP6), thus, blocking Wnt/b-catenin signaling and Wnt-mediated growth and migration in MDA-MB-231 breast cancer cells. Kallistatin inhibited Wnt3a-induced proliferation, migration, and invasion of cultured breast cancer cells. Moreover, kallistatin was bound to LRP6 in breast cancer cells, as identified by immunoprecipitation followed by western blot. Kallistatin suppressed Wnt3a-mediated phosphorylation of LRP6 and glycogen synthase kinase-3b, and the elevation of cytosolic b-catenin levels. Furthermore, kallistatin antagonized Wnt3a-induced expression of c-Myc, cyclin D1, and vascular endothelial growth factor. These findings indicate a novel role of kallistatin in preventing breast tumor growth and mobility by direct interaction with LRP6, leading to blockade of the canonical Wnt signaling pathway.
Introduction
The Wnt proteins are a group of secreted cysteine-rich glycoproteins that are involved in differentiation events during embryonic development, and can lead to tumor formation when aberrantly activated [1] . Activation of the canonical Wnt pathway involves stabilization of b-catenin through binding of Wnt ligands to cell-surface receptors: Frizzled (Fz) family receptors and low-density lipoprotein receptor-related proteins (LRP5 or LRP6). However, in the absence of Wnt ligands, b-catenin is phosphorylated by a protein complex containing glycogen synthase kinase 3b (GSK-3b), leading to ubiquitination and targeting for degradation by the proteasome. Upon binding of certain Wnt ligands, Fz receptor binds to LRP5/6, resulting in the phosphorylation of LRP6 and subsequent blockade of b-catenin phosphorylation by GSK-3b [2, 3] . The nonphosphorylated form of b-catenin accumulates in the cytoplasm and is translocated to the nucleus where it acts as a cotranscriptional activator in regulating downstream target genes to promote cell proliferation, differentiation, and tissue development [4] [5] [6] . Moreover, Wnt/b-catenin signaling has been shown to be the primary pathway for Wnt-mediated oncogenesis in the mammary gland [7] .
Kallistatin (KS), a plasma protein, has been demonstrated to exert multiple biologic functions. Plasma levels of KS are known to be reduced in patients with sepsis, liver disease [8] , obesity [9] , as well as various cancers (unpublished observations). KS's pleiotropic effects include inhibiting angiogenesis, inflammation, tumor growth, and metastasis in animal models and cultured cells [10] [11] [12] [13] [14] . KS suppressed tumor growth and angiogenesis in nude mice via antagonizing VEGF-mediated cell proliferation, migration, and invasion of cultured endothelial cells [10, 11] . KS also inhibited inflammation via competing with the binding of tumor necrosis factor (TNF)-a to its receptor, thus reducing NF-jB activation and pro-inflammatory gene expression in endothelial cells [14] . Moreover, a previous study has shown that SERPINA3K (KS) blocked Wnt ligand-induced signaling by binding to LRP6 in retinal epithelial cells, leading to inhibition of retinal neovascularization [15] . The aim of the present study is to determine the effect of KS on canonical Wnt signaling and cancer cell mobility through interaction of Wnt3a with LPR6 in human breast cancer MDA-MB-231 cells.
Materials and methods

Cell culture and recombinant human kallistatin
The human breast cancer cell-line MDA-MB-231 was chosen for this study because of their high expression of LRP6 [16] . MDA-MB-231 cells were obtained from Americantype culture collection (ATCC) and grown in high-glucose Dulbecco's modified Eagle's medium (DMEM; Invitrogen, CA) supplemented with 2 mM L-glutamine and 10 % FBS (Atlanta Biologicals, GA). Recombinant human KS was expressed and secreted into the serum-free medium of cultured HEK293 cells. The cultured medium was concentrated by ammonium sulfate precipitation and then purified by nickel-affinity chromatography as previously described [17] . The purity and identity of human KS were verified by SDS-PAGE and western blot analysis, using a specific monoclonal antibody [8] .
Cell proliferation, migration, and invasion assays MDA-MB-231 cells were serum-deprived, pretreated with KS (0.5 lM) for 30 min, and then cultured with Wnt3a (100 ng/ml) for 24 h prior to the addition of 5-bromo-2 0 -deoxyuridine (BrdU) for an additional 2 h before performing the Cell Proliferation ELISA, BrdU colorimetric assay (Roche Applied Science, IN). Modified Boyden's chambers (Corning Incorporated, GA) were used to quantify cell migration and invasion as previously described [18] .
Immunoprecipitation and western blot Immunoprecipitation was performed as described previously [19] . Anti-KS polyclonal antibody [8] or anti-LRP6 antibody (5 lg) (Cell Signaling, MA) was used to precipitate 1 mg of whole cell lysate. The precipitates and input samples were then immunoblotted with antibodies for LRP6 and monoclonal antibody against KS (G4C10), respectively [8] . For western blot, cultured MDA-MB-231 cells were serum-deprived, pretreated with KS at different concentrations (0.5, 1 or 2 lM) for 30 min or left untreated, and then stimulated with Wnt3a (100 ng/ml) (R&D Systems, MN) for 2 or 24 h for different experiments. Cell extracts were subjected to western blot analysis for the detection of phosphorylated LPR6 and GSK-3b, nonphosphorylated b-catenin, as well as total LPR6, GSK-3b, b-catenin, cyclin D1 (Cell Signaling, MA), and c-Myc (Santa Cruz, CA). GAPDH was used as a loading control (BioAbchem, SC).
Quantitative real-time polymerase chain reaction (PCR)
Total RNA was extracted with TRIzol reagent (Invitrogen, CA). RNA was then reverse transcribed with a cDNA archive kit (Applied Biosystems, CA). Quantitative realtime PCR was carried out on a 7300 real-time PCR system (Applied Biosystems, CA) and normalized against 18S RNA (Hs99999901_ml). The following primers were used: c-Myc (Hs00905030_m1), cyclin D1 (Hs00765553_m1), and VEGF (Hs00173626_ml).
Enzyme-linked immunosorbent assay (ELISA)
Levels of VEGF in the cell culture media were measured by DuoSet ELISA development system (R&D Systems, MN) according to the manufacturer's protocol.
Statistical analysis
Data are presented as mean ± SEM and compared among experimental groups with the use of a one-way ANOVA followed by Newman-Keuls multiple comparison test. A difference of P \ 0.05 was considered statistically significant.
Results
Kallistatin inhibits Wnt3a-induced proliferation, migration, and invasion of breast cancer cells
The effects of human KS on the proliferation of tumor cells in response to Wnt pathway activation were investigated. We measured BrdU uptake by MDA-MB-231 breast cancer cells treated with or without Wnt3a (100 ng/ml) in the presence or absence of KS (0.5 lM). As shown in Fig. 1a , Wnt3a markedly increased MDA-MB-231 cell proliferation about 1.6-fold compared with nonstimulated cells, but the effect was abolished by KS. KS, in the absence of Wnt3a, had no effect on cell proliferation in MDA-MB-231 cells, as determined by both BrdU uptake and 3 H-thymidine incorporation (unpublished results). Moreover, the migration and invasion of Wnt3a-treated cells significantly increased 1.5-and 1.3-fold, respectively, compared with control cells, and KS attenuated these effects (Fig. 1b, c) .
Kallistatin binds to Wnt-coreceptor LRP6
To determine whether KS specifically binds to Wnt-coreceptor LRP6, MDA-MB-231 cells were placed in serumfree medium with and without human KS (0.2 lM) for 2 h. Western blot analysis using anti-KS antibody showed that LRP6 was present in both control and KS-treated input samples, but was only coprecipitated in KS-treated cell extracts (Fig. 2a) . To further confirm the interaction between LRP6 and KS, LRP6 antibody was used for immunoprecipitation followed by western blot analysis, thus showing that LRP6 coprecipitated with KS (Fig. 2b) . These results indicate that KS specifically bound to the Wnt coreceptor LRP6 in MDA-MB-231 cells.
Kallistatin suppresses Wnt/b-catenin signaling
Given the direct interaction of KS with LRP6, we next investigated whether KS could modulate Wnt/b-catenin signaling. MDA-MB-231 breast cancer cells were treated with Wnt3a (100 ng/ml) for different time periods. Western blot analysis of cell lysates showed that Wnt3a began to induce phosphorylation of LRP6 at 1 h, peaked at 2 h, and then returned to basal levels at 24 h (Fig. 3a) . The change in phosphorylated GSK-3b and nonphosphorylated b-catenin levels paralleled that of phosphorylated LRP6 during the same time course. However, cytosolic b-catenin levels did not return to the basal level at 24 h. Based on the time course results, we selected 2 h as the time point for KS treatment. Cells were pretreated, with or without KS, at different concentrations (1 or 2 lM) for 30 min, followed by incubation with Wnt3a (100 ng/ml) for 2 h. Western blot analysis revealed that Wnt3a treatment increased LRP6 phosphorylation, and the effect was suppressed by both doses of KS (Fig. 3b) . The 2-lM dose of KS reduced Wnt3a-induced phosphorylated GSK-3b levels. In addition, nonphosphorylated b-catenin levels in the cytosol were significantly decreased by the 2-lM dose of KS. MDA-MB-231 breast cancer cells, we examined the Wnt/ b-catenin target genes that have documented roles in cell proliferation, migration, and invasion-namely c-Myc, cyclin D1, and VEGF [20] [21] [22] [23] . After treatment of MDA-MB-231 cells with Wnt3a (100 ng/ml) for 24 h, the protein levels of c-Myc, cyclin D1, and VEGF were increased, but were attenuated by KS pre-treatment at 0.5 lM (Fig. 4a, c,  e) . Similarly, KS significantly blocked Wnt3a-mediated increases of c-Myc, cyclin D1, and VEGF mRNA levels (Fig. 4b, d, f) .
Discussion
This is the first study to demonstrate that KS inhibits the Wnt/b-catenin signaling cascade in breast cancer cells. Our results showed that KS forms a complex with the Wnt coreceptor LRP6, thereby antagonizing Wnt3a-induced phosphorylation of LRP6 and GSK-3b, and suppressing cytosolic b-catenin levels. KS treatment also retarded the growth and motility of MDA-MB-231 breast cancer cells in association with the downregulated expression of c-Myc, cyclin D1, and VEGF induced by Wnt3a. A schematic depicting the effect of KS on Wnt/b-catenin signaling is shown in Fig. 5 . In the present study, KS specifically bound to Wnt coreceptor LRP6 in human breast cancer cells, as demonstrated by the method of immunoprecipitation followed by immunoblot. Consequently, KS pretreatment reduced Wnt3a-induced LRP6 and GSK-3b phosphorylation and cytosolic nonphosphorylated b-catenin levels in MDA-MB-231 cells. These findings are consistent with the report that KS (SERPINA3K) bound to LRP6 in retinal epithelial cells [15] . Specific binding of KS to LRP6 on MDA-MB-231 cells indicated that the inhibitory effect of KS on Wnt-mediated actions, such as cell proliferation, migration, invasion, and target gene expression, is at the Wnt receptor level. Dimerization between LRP6 and Fz is the first step in the activation of the Wnt pathway [24] . By specifically binding to LRP6, KS may prevent LRP6 and Fz dimerization induced by Wnt ligand. We previously showed that KS exerts its pleiotropic actions through two important structural elements: the active site and a heparinbinding domain [25] [26] [27] . KS via its active site inhibits tissue kallikrein activity. Moreover, through its heparinbinding domain, KS has been shown to compete with TNF-a binding to endothelial cells and thus inhibit TNF-ainduced NF-jB activation and proinflammatory gene expression [14] . KS, but not its heparin mutant, was also demonstrated to suppress VEGF-induced proliferation, migration, and permeability in endothelial cells [11] . Studies have indicated that LRP binds to a synthetic heparin-mimicking compound on the surface of vascular smooth muscle cells [28] and functions as a heparindependent adhesion receptor for connective tissue growth factor in hepatic cells [29] . Therefore, it is likely that KS binds to LRP6 via its heparin-binding site. The mechanism by which KS interacts with LRP6 awaits further investigation.
Both c-Myc and cyclin D1 have been identified as target genes of the Wnt/b-catenin signaling pathway [23, 30] . Aberrant expression of cyclin D1 and c-Myc is mainly dependent on alterations in the Wnt signaling pathway in breast cancer [31] . Our studies here showed that activation of Wnt/b-catenin signaling enhanced c-Myc expression, which was paralleled by an increase in expression of the c-Myc-dependent gene cyclin D1. Cyclin D1 is one of the cell cycle-regulating oncoproteins, playing a pivotal role not only in breast carcinogenesis, but also development of the mammary gland [32] . We found that KS treatment significantly diminished Wnt3a-induced expression of c-Myc and cyclin D1 in breast cancer cells. This finding is consistent with the report that expression of c-Myc and cyclin Dl is markedly decreased in LRP6-knockout MDA-MB-231 cells [16] . In addition, we showed that the binding of KS to LRP6, which would lower the phosphorylation of LRP6 induced by Wnt, led to an expected decrease in cytosolic b-catenin levels as well as reduced c-Myc and cyclin D1 transcriptional activity. Moreover, we demonstrated that KS significantly inhibited Wnt3a-induced MDA-MB-231 cell proliferation. The antiproliferative effects of KS are most likely due to the inhibition of cyclin D1 expression, as cyclin D1 is required for DNA synthesis and cell cycle progression [33] . Our studies also showed that KS inhibited Wnt3a-induced migration and invasion of human breast cancer cells, possibly through reduction of VEGF expression. VEGF is a major inflammatory and angiogenic factor, as well as a target gene of the Wnt pathway [6] . A previous study showed that the migration and invasion of human cancer cells are attributed to expression of VEGF and its receptors [34] . VEGF is expressed by many epithelial cancer cells, including human breast carcinomas. Recently, it has been shown that VEGF receptors are also present on the surface of breast cancer cells [35] . VEGF secreted by epithelial cells stimulates the PI3-kinase/Akt signaling pathway, leading to cellular migration and invasion of breast cancer cells [35, 36] . Thus, by reducing VEGF expression, KS may potentially prevent breast cancer metastasis.
In this study, we identified a novel signaling pathway mediated by KS in inhibiting the proliferation, migration, and invasion of mesenchymal-like MDA-MB-231 breast cancer cells. Our results showed that KS blocked Wnt3a-mediated canonical Wnt signaling in breast cancer cells by direct interaction with the Wnt coreceptor LRP6. Wnt/ b-catenin signaling plays a crucial role in carcinogenesis [37] . Moreover, LRP6 overexpression has been characterized in a breast cancer subtype, and therefore is a potential therapeutic target in breast cancer treatment [16] . These findings indicate a potential new role for KS in preventing oncogenesis in the mammary gland. Our previous studies demonstrated that KS is an inhibitor of angiogenesis, inflammation, tumor growth, and metastasis in animal models and in cultured cells by antagonizing VEGF-and TNF-a-mediated signaling pathways [10] [11] [12] [13] [14] . The current study reveals a novel mechanism mediated by KS via antagonizing canonical Wnt signaling, leading to retardation of tumor progression. Our findings provide essential insights for the biological role of KS in tumor growth and progression. KS administration and KS-deficiency approaches would further establish the effect of KS on Wnt/b-catenin signaling and LRP6 interactions in carcinogenesis.
In summary, our present studies indicate that KS is a modulator of the Wnt pathway. Importantly, we have identified a new action of KS in inhibiting tumor growth and motility through direct interaction with Wnt coreceptor and subsequent blockade of Wnt/b-catenin signaling. The inhibition of cell proliferation, migration, and invasion of breast cancer cells via KS administration provides evidence for its potential for cancer treatment. Indeed, KS gene delivery was shown to inhibit experimental lung metastasis in mice [12] . Taken together, our findings suggest that interference of canonical Wnt signaling at the ligandreceptor level, in combination with other targeted therapies, may improve the efficacy of breast cancer treatment.
